Goldman Sachs
BCAX

Goldman Sachs’s Bicara Therapeutics BCAX Stock Holding History

Goldman Sachs’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$15.5M Sell
520,567
-38,397
-7% -$857K ﹤0.01% 2882
2026
Q1 		$11.1M Buy
558,964
+6,633
+1% +$114K ﹤0.01% 2989
2025
Q4 		$9.3M Buy
552,331
+319,570
+137% +$5.46M ﹤0.01% 3160
2025
Q3 		$3.68M Buy
232,761
+80,904
+53% +$906K ﹤0.01% 3930
2025
Q2 		$1.41M Buy
151,857
+26,162
+21% +$312K ﹤0.01% 4443
2025
Q1 		$1.64M Sell
125,695
-54,054
-30% -$718K ﹤0.01% 4321
2024
Q4 		$3.13M Buy
179,749
+77,854
+76% +$1.62M ﹤0.01% 3914
2024
Q3 		$2.6M Buy
+101,895
New +$2.6M ﹤0.01% 3920

Other funds holding BCAX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
RTM
Red Tree Management Redwood City, California $147M AUM 202.18% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Goldman Sachs's BCAX Position: Q2 2026 in Review

Goldman Sachs reduced its Bicara Therapeutics (BCAX) stake by 6.9% in Q2 2026, selling an estimated $857K and leaving 520,567 shares worth $15.5M. The position accounts for ﹤0.01% of the portfolio, ranked #2882.

Goldman Sachs first reported a position in BCAX in Q3 2024 and has held it in 8 quarters since. 172 funds tracked by Wall St. Rank hold BCAX as of Q2 2026.

  • Goldman Sachs held 520,567 shares of Bicara Therapeutics worth $15.5M as of Q2 2026.
  • Goldman Sachs sold 38,397 Bicara Therapeutics shares in Q2 2026, an estimated $857K.
  • Bicara Therapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #2882 holding.
  • Goldman Sachs first reported a position in Bicara Therapeutics in Q3 2024 and has held it in 8 quarters since.
  • 172 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.